Current treatment of significant left main coronary artery disease: A  review
Though infrequent, left main stenosis has a major prognostic impact. The management of left main disease has evolved over the last few decades with the growing evidence of the efficacy and safety of percutaneous interventions, as attested by the most recent trials.However, mastery of the technical aspects of left main bifurcation stenting is essential in ensuring optimal results. This review focuses on recent data concerning left main angioplasty results as well as the current technical approaches. (Source: Trends in Cardiovascular Medicine)
Source: Trends in Cardiovascular Medicine - January 5, 2018 Category: Cardiology Authors: Mariama Akodad, Marie-Claude Morice Source Type: research

Current treatment of significant left main coronary artery disease: A review
Though infrequent, left main stenosis has a major prognostic impact. The management of left main disease has evolved over the last few decades with the growing evidence of the efficacy and safety of percutaneous interventions, as attested by the most recent trials.However, mastery of the technical aspects of left main bifurcation stenting is essential in ensuring optimal results. This review focuses on recent data concerning left main angioplasty results as well as the current technical approaches. (Source: Trends in Cardiovascular Medicine)
Source: Trends in Cardiovascular Medicine - January 5, 2018 Category: Cardiology Authors: Mariama Akodad, Marie-Claude Morice Source Type: research

Current use of beta-blockers in patients with coronary artery disease
Beta-blockers have long comprised a cornerstone in the symptomatic treatment of ischemic heart disease and in the secondary prevention of myocardial infarction and heart failure. The majority of studies underlying the evidence of a beneficial effect of beta-blockers on outcomes were conducted more than 25 years ago. In a contemporary era where treatment strategies and secondary prophylactic therapy have undergone several changes, the continued role of beta-blockers in ischemic heart disease has been questioned, especially in the absence of heart failure or a recent myocardial infarction. (Source: Trends in Cardiovascular Medicine)
Source: Trends in Cardiovascular Medicine - January 5, 2018 Category: Cardiology Authors: Charlotte Andreasen, Charlotte Andersson Source Type: research

Editorial commentary: Newborn screening for Fabry disease: Too much too soon?
The possibility to perform newborn screening for many lysosomal storage disorders, using tandem mass spectrometry (MS/MS), is undoubtedly going to change the prospect for patients with these conditions. By providing the opportunity to treat before patients become symptomatic, it may prevent complications and improve quality of life, as has been shown for other inherited metabolic disorders. Examples of successful interventions following the introduction of newborn screening are dietary measures in glutaric aciduria type I, which dramatically reduced the occurrence of movement disorders early in life [1] and NTBC treatment ...
Source: Trends in Cardiovascular Medicine - January 5, 2018 Category: Cardiology Authors: M. Langeveld Source Type: research

Current use of beta-blockers in patients with coronary artery disease
Beta-blockers have long comprised a cornerstone in the symptomatic treatment of ischemic heart disease and in the secondary prevention of myocardial infarction and heart failure. The majority of studies underlying the evidence of a beneficial effect of beta-blockers on outcomes were conducted more than 25 years ago. In a contemporary era where treatment strategies and secondary prophylactic therapy have undergone several changes, the continued role of beta-blockers in ischemic heart disease has been questioned, especially in the absence of heart failure or a recent myocardial infarction. (Source: Trends in Cardiovascular Medicine)
Source: Trends in Cardiovascular Medicine - January 5, 2018 Category: Cardiology Authors: Charlotte Andreasen, Charlotte Andersson Source Type: research

Current treatment of significant left main coronary artery disease: A review
Though infrequent, left main stenosis has a major prognostic impact. The management of left main disease has evolved over the last few decades with the growing evidence of the efficacy and safety of percutaneous interventions, as attested by the most recent trials.However, mastery of the technical aspects of left main bifurcation stenting is essential in ensuring optimal results. This review focuses on recent data concerning left main angioplasty results as well as the current technical approaches. (Source: Trends in Cardiovascular Medicine)
Source: Trends in Cardiovascular Medicine - January 5, 2018 Category: Cardiology Authors: Mariama Akodad, Marie-Claude Morice Source Type: research

Current use of beta blockers in patients with coronary artery disease
Beta-blockers have long comprised a cornerstone in the symptomatic treatment of ischemic heart disease and in the secondary prevention of myocardial infarction and heart failure. The majority of studies underlying the evidence of a beneficial effect of beta-blockers on outcomes were conducted more than 25 years ago. In a contemporary era where treatment strategies and secondary prophylactic therapy have undergone several changes, the continued role of beta-blockers in ischemic heart disease has been questioned, especially in the absence of heart failure or a recent myocardial infarction. (Source: Trends in Cardiovascular Medicine)
Source: Trends in Cardiovascular Medicine - January 5, 2018 Category: Cardiology Authors: Charlotte Andreasen, Charlotte Andersson Source Type: research

Editorial Commentary: Newborn screening for Fabry disease: too much too soon?
The possibility to perform newborn screening for many lysosomal storage disorders, using tandem mass spectrometry (MS/MS), is undoubtedly going to change the prospect for patients with these conditions. By providing the opportunity to treat before patients become symptomatic, it may prevent complications and improve quality of life, as has been shown for other inherited metabolic disorders. Examples of successful interventions following the introduction of newborn screening are dietary measures in glutaric aciduria type I, which dramatically reduced the occurrence of movement disorders early in life [1] and NTBC treatment ...
Source: Trends in Cardiovascular Medicine - January 5, 2018 Category: Cardiology Authors: M. Langeveld Source Type: research

Epigenetic mechanisms in coronary artery disease: The current state and prospects
Coronary artery disease (CAD) is the leading cause of morbidity and mortality. CAD has both genetic and environmental causes. In the past two decades, the understanding of epigenetics has advanced swiftly and vigorously. It has been demonstrated that epigenetic modifications are associated with the onset and progression of CAD. This review aims to improve the understanding of the epigenetic mechanisms closely related to CAD and to provide a novel perspective on the onset and development of CAD. Epigenetic changes include DNA methylation, histone modification, microRNA and lncRNA, which are interrelated with critical genes ...
Source: Trends in Cardiovascular Medicine - December 30, 2017 Category: Cardiology Authors: Lian Duan, Chao Liu, Junyuan Hu, Yongmei Liu, Jie Wang, Guang Chen, Zhaoling Li, Hengwen Chen Source Type: research

LDL cholesterol: How low to go?
Epidemiology and the results of large-scale outcome trials indicate that the association of LDL with atherosclerotic cardiovascular disease is causal, and continuous not only across levels seen in the general population but also down to sub-physiological values. There is no scientific basis, therefore, to set a target or ‘floor’ for LDL cholesterol lowering, and this presents a clinical and conceptual dilemma for prescribers, patients, and payers. With the advent of powerful agents such as proprotein convertase/subtilisin kexin type 9 (PCSK9) inhibitors, LDL cholesterol can be lowered profoundly but health econo mic co...
Source: Trends in Cardiovascular Medicine - December 28, 2017 Category: Cardiology Authors: Chris J. Packard Source Type: research

LDL cholesterol – How low to go?
Epidemiology and the results of large-scale outcome trials indicate that the association of LDL with atherosclerotic cardiovascular disease is causal, and continuous not only across levels seen in the general population but also down to sub-physiological values. There is no scientific basis, therefore, to set a target or ‘floor’ for LDL cholesterol lowering, and this presents a clinical and conceptual dilemma for prescribers, patients and payers. With the advent of powerful agents such as proprotein convertase/subtilisin kexin type 9 (PCSK9) inhibitors, LDL cholesterol can be lowered profoundly but health econom ic con...
Source: Trends in Cardiovascular Medicine - December 28, 2017 Category: Cardiology Authors: Chris J. Packard Source Type: research

ACE inhibition to slow progression of myocardial fibrosis in muscular dystrophies
Muscular dystrophy (MD) connotes a heterogeneous group of inherited disordersaffecting skeletal and cardiac muscle. Inseveral forms of MD, the cardiac disease may be the predominant manifestationof the underlying genetic myopathy. The cardiacinvolvement is due to progressive interstitial fibrosis and fatty replacement inboth the atria and ventricles, which may lead to cardiomyopathy, conductiondefects and tachyarrhythmias. Angiotensin-convertingenzyme inhibitors (ACE-Is) modulate the production of angiotensin II and limitthe amount of fibrosis in the myocardium, reducing mortality andhospitalization in cardiac patients. (S...
Source: Trends in Cardiovascular Medicine - December 21, 2017 Category: Cardiology Authors: Vincenzo Russo, Andrea Antonio Papa, Emmanuel Ato Williams, Anna Rago, Alberto Palladino, Luisa Politano, Gerardo Nigro Source Type: research

Editorial commentary: Malignant PVCs: Revising the ‘idiopathic’ label
Premature ventricular contractions (PVCs) are commonly seen on routine ECGs, telemetry and Holter monitoring. When PVCs cause symptoms of palpitations or fatigue, ablation or medical therapy can be very effective. However, in the absence of symptoms, PVCs are frequently dismissed by healthcare providers without further evaluation. In the past few decades, our understanding has progressed to identify that PVCs may result in significant morbidity beyond symptoms. In this issue of Trends in Cardiovascular Medicine, Drs. (Source: Trends in Cardiovascular Medicine)
Source: Trends in Cardiovascular Medicine - December 21, 2017 Category: Cardiology Authors: Gregory E. Supple Source Type: research